Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for serious or life-threatening diseases with significant unmet needs. Its lead product candidate is AIR001, a sodium nitrite solution for inhalation through nebulization, which is in Phase II clinical stage for the treatment of heart failure with preserved ejection fraction, as well as in Phase I/II study in patients with cystic fibrosis. The company was formerly known as ADVENTRX Pharmaceuticals, Inc. and changed its name to Mast Therapeutics, Inc. in March 2013. Mast Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
http://www.priceseries.com/trade/SVRA-Savara-Inc-stock-gains-59-percent-a-Trade-Record-by-priceSeries-2017111020171226.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments